Population prevalence, penetrance, and mortality for genetically confirmed MODY
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Context
Diagnosing Maturity-Onset Diabetes of the Young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studies of MODY are prone to ascertainment bias, limiting accurate estimates of its population prevalence and phenotypic spectrum.
Objective
To apply a genotype-first approach to determine the population prevalence, penetrance, and all-cause mortality associated with MODY.
Methods
We analysed exome sequencing and clinical data from 454,275 UK Biobank participants to identify pathogenic variants in 10 established MODY genes. We assessed variant prevalence, age-dependent diabetes penetrance, and all-cause mortality by genetic aetiology over a mean follow-up of 13.4 years.
Results
Pathogenic MODY variants were present in 1 in 1,052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40. GCK variants were the most frequent (1 in 2,787), demonstrating high penetrance (mean HbA1c 8.8 mmol/mol higher; 94.5% with prediabetes or diabetes) but no significant association with all-cause mortality ( P =0.09). Variants in other MODY genes showed lower penetrance, with 12% of carriers developing diabetes by age 40 and 31.6% by age 60 and showed no increase in all-cause mortality ( P =0.89). Penetrance varied by genetic aetiology, with HNF1A showing the highest penetrance and PDX1 , NEUROD1 , and RFX6 the lowest. Parental history of diabetes and polygenic risk for type 2 diabetes were important modifiers of penetrance (Hazard ratios 2.54 and 1.52 respectively, P <3.9×10 −3 ).
Conclusions
This large-scale genotype-first study provides novel insights into MODY in the population. These findings have broad implications for genetic counselling, personalised treatment strategies, and healthcare resource allocation.
